Collaborative Innovation in CDMOs: Interview Series with Pharmaceutical Technology
Part 1: Early Engagement, IP Strategy, and Advanced Formulation
In Part 1 of the interview series, Dr. Dave Miller Ph.D. (CSO) explores why engaging a CDMO at the earliest stages of development can unlock significant strategic advantages. Miller discusses how early collaboration enables stronger IP protection, informed formulation design, and alignment between clinical and commercial objectives. The piece highlights AustinPx’s ability to tailor solutions that anticipate regulatory, manufacturing, and market needs from the outset, helping sponsors avoid costly missteps and protect long-term asset value.
Part 2: The Importance for CDMOs of Partnering With a Sponsor’s Mindset
In this feature, Dr. Dave Miller Ph.D. explains how AustinPx’s roots as a pharmaceutical sponsor shape its approach to partnerships. By thinking like a developer, the team prioritizes scientific depth, asset protection, and strategic alignment across the entire drug lifecycle. The article illustrates how this mindset builds stronger, more collaborative relationships that go beyond transactional services to deliver solutions that perform in the clinic, at market launch, and over the product’s lifetime.